Bruce D. Gelb

DIRECTOR CHILD HEALTH AND DEVELOPMENT INSTITUTE
PROFESSOR Pediatrics, Cardiology
PROFESSOR Genetics and Genomic Sciences

Print Profile

Email

bruce.gelb@mssm.edu

Specialty

Pediatric Cardiology

Certifications

Pediatric Cardiology

Clinical Focus

Cardiomyopathy
Noonan Syndrome

Research Topics

Training Areas

Genetics and Genomic Sciences [GGS]

Education

MD, Univ. of Rochester Sch. Med. & Den.
Residency, Pediatrics
Columbia-Presbyterian Medical Ctr.
Fellowship, Pediatric Cardiology
Texas Children's Hospital

Biography

Center for Molecular Cardiology

Awards

2010 -
Best Doctors
New York Magazine

Research

Specific Clinical/Research Interests:
Genetics of congenital heart defects; Noonan syndrome and related disorders; Gain-of-function RAS signaling

Postdoctoral Fellows: Dhandapany Perundurai, Constance Weismann, Sherly Pardo, Sonia Mulero

Research Personnel: Kimihiko Oishi, Jiang Zhang, Bobby Faigen, Jessica Hamaker, Mehran Sourian

Summary of Research Studies:
The Gelb research group is focused on disease gene discovery using positional cloning/candidacy techniques and characterization of the biological roles of such genes in disease pathogenesis. The focus of the laboratory currently is on those traits that are associated with heart malformations. In the past few years, we have identified disease genes for Char and Noonan syndromes. The former is TFAP2B, which encodes a transcription factor of the AP-2 family, and the latter are PTPN11, KRAS, SOS1, and RAF1. We are studying the roles of these disease genes in normal developmental and homeostatic processes as well as in disease pathogenesis. We are actively studying additional human genetic traits, both simple and complex, to identify additional disease genes with a particular focus on traits with cardiovascular abnormalities. After recruiting families of adequate size inheriting disorders, we undertake genome-wide scans with polymorphic DNA markers to identify genetic loci t! hrough linkage analysis, and then identify disease genes from among known or predicted genes residing in disease loci. The latter relies heavily on bioinformatics, including several software packages that predict genes and protein function. Ongoing biologic studies include site-directed mutagenesis, expression of wild type and mutant proteins in vitro and in eukaryotic cell culture, immunolocalization of proteins, creation of transgenic mice, and phenotyping of mouse models. We are also studying disease genes in other model organisms such as Drosophila melanogaster. Finally, we are studying induced pluripotent stem cells (iPS) derived from skin fibroblasts from patients with Noonan syndrome and other RAS signaling disorders.

Publications

Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, Lopez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genet 2007; 39: 1007-1012.

Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JL, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nature Genet 2007; 39: 75-79.

Oishi K, Gaengel K, Krishnamoorthy S, Kamiya K, Kim I, Ying H, Weber U, Perkins L, Tartaglia M, Mlodzik M, Pick L, Gelb BD. Transgenic Drosophila models of Noonan syndrome-causing PTPN11 gain-of-function mutations. Hum Molec Genet 2006; 15: 543-553.

Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Hahlen K, Hasle H, Jung A, Licht JD, Gelb BD. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003 Jun; 34(2): 148-150.

Oishi K, Hofmann S, Diaz GA, Brown T, Manwani D, Ng L, Young R, Vlassara H, Ioannou YA, Forrest D, Gelb BD. Targeted disruption of Slc19a2, the gene encoding the high-affinity thiamin transporter Thtr-1, causes diabetes mellitus, sensorineural deafness and megaloblastosis in mice. Hum Mol Genet 2002 Nov; 11(23): 2951-2960.

Clinical Trials

Beta Blocker Therapy vs. Angiotensin II in Marfan

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Gelb during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

RTI International

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

Shire; Signature Genomics

Royalty Payments:

Correlagen Diagnostics, Inc.; GeneDx; Pfizer Inc.; PreventionGenetics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central